Biotechnology company ImmunoScape has signed a collaboration with Singapore’s Experimental Drug Development Centre (EDDC) to develop new TCR-based bispecific molecules for solid tumours.
ImmunoScape will utilise its catalogue of tumour-specific TCR candidates to co-develop off-the-shelf TCR-based bispecific molecules with EDDC.
These molecules have two separate binding sites and are created to attach to and trigger T cells. This guides them towards tumour areas to interact with cells that express the appropriate tumour-specific antigen through the TCR.
This helps the patient’s T cell repertoire to eradicate cancer cells selectively.
EDDC will contribute its expertise in therapeutic protein design and antibody engineering for the development of these bispecific molecules.
The parties will commence the work under the partnership early in 2024.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
ImmunoScape CEO Choon-Peng Ng stated: “The benefit of off-the-shelf TCR molecules is that they do not require engineering and manufacturing of the patient’s own T cells, which can make them accessible to a much broader patient population and further results in much lower production costs and shorter timelines for the patients to receive the drug.
“By combining the power of our machine learning-augmented TCR discovery platform with EDDC’s broad expertise in the design of multifunctional constructs, we will aim to rapidly develop novel off-the-shelf TCR-based bispecific molecules that could overcome widespread challenges in cell therapy approaches against solid tumours.”
ImmunoScape discovers and develops next-generation TCR cell therapies for oncology indications.
Its deep Immunomics technology and machine learning platforms aid in conducting large-scale mining and immune profiling of T cells using samples of cancer patients to detect new, therapeutically significant TCRs across a range of solid tumour types.
The company has several programmes in the discovery stage and plans to advance them to investigational new drug application-enabling studies and subsequent clinical trials.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.